Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy

57Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

While anti-angiogenic therapy was initially greeted enthusiastically by the cancer community, initial successes with this therapeutic modality were tempered by the failure of angiogenesis inhibitors to produce sustained clinical responses in most patients, with resistance to the inhibitors frequently developing. We recently reported that hypoxia increases after the devascularization caused by anti-angiogenic therapy, consistent with the goals of these therapies, but that some tumor cells become resistant and survive the hypoxic insult elicited by anti-angiogenic therapy through autophagy by activating both AMPK and HIF1A pathways. These findings suggest that modulating the autophagy pathway may someday allow anti-angiogenic therapy to fulfill its therapeutic potential. However, further work will clearly be needed to develop more potent and specific autophagy inhibitors and to better understand the regulators of autophagy in malignant cells. © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Hu, Y. L., Jahangiri, A., De Lay, M., & Aghi, M. K. (2012). Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy, 8(6), 979–981. https://doi.org/10.4161/auto.20232

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free